May 13th 2024
Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Determining Racial Disparities Related to Acute Kidney Injury in NSCLC
December 8th 2021Nino Balanchivadze, MD, FACP, discusses the methods used in the retrospective analysis of KEYNOTE-189 study, to determine the differences in the rate of renal toxicity based on race in patients with non-squamous non-small cell lung cancer.
Watch
Efficacy and Safety of Frontline Treatment Options for ALK+ NSCLC
November 30th 2021Karen Reckamp, MD, and Jyoti Patel, MD, review currently available frontline treatment options for ALK+ advanced NSCLC and discuss updated efficacy and safety data from key clinical trials of these agents in advanced NSCLC.
Watch
United We Stand, Divided We Fall: Addressing High Lung Cancer Rates, Mortality in Kentucky
November 23rd 2021From scientists to oncologists and other clinicians in the community setting, years of research has grasped the big picture of lung cancer occurrence and outcomes in Kentucky, and some have begun to investigate potential causes.
Read More
Next-Generation ALK Inhibitor Ensartinib Outperforms Crizotinib in ALK-Positive NSCLC
November 22nd 2021Ensartinib, an investigational ALK inhibitor, significantly extended progression-free survival versus crizotinib in patients with advanced disease in the phase 3 eXalt3 randomized clinical trial.
Read More
Part 1: Challenges in Performing Biopsies and Molecular Testing in NSCLC
November 12th 2021At a live virtual event, Martin Dietrich, MD, PhD, discusses how to approach biopsies and molecular testing in coordination with pathologists and testing services for patients with non–small cell lung cancer.
Read More
Nivolumab Shows Promise as a Second-Line Option for Malignant Mesothelioma
November 5th 2021Until the CONFIRM results, no phase 3 trial had demonstrated improvement survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy.
Read More